|Articles|May 1, 2017
- Pharmaceutical Executive-05-01-2017
- Volume 37
- Issue 5
Pharmaceutical Executive, May 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 8 years ago
Brand of the Year: A Retrospectiveover 8 years ago
Portfolio Management Health Checkover 8 years ago
Launch for Long-Term Successover 8 years ago
Merck’s Latest Shot Against Shinglesover 8 years ago
Measuring the Value of Prescription Drugsover 8 years ago
New Life in European Drug Pricing Spatover 8 years ago
Country Report: SwitzerlandNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
3
Merck to Acquire Cidara for $9.2 Billion
4
DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026
5
